Daniel R. Hart
2019
Compensation breakdown
| Non-Equity Incentive Plan | $84,300 |
|---|---|
| Option Awards | $400,672 |
| Salary | $270,981 |
| Other | $32,436 |
| Total | $788,389 |
Hart received $400.7K in option awards, accounting for 51% of the total pay in 2019.
Hart also received $84.3K in non-equity incentive plan, $271K in salary and $32.4K in other compensation.
Rankings
In 2019, Daniel R. Hart's compensation ranked 10,275th out of 13,971 executives tracked by ExecPay. In other words, Hart earned more than 26.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,275 out of 13,971 | 27th |
Division Manufacturing | 4,158 out of 5,701 | 27th |
Major group Chemicals And Allied Products | 1,594 out of 2,200 | 28th |
Industry group Drugs | 1,365 out of 1,886 | 28th |
Industry Pharmaceutical Preparations | 1,015 out of 1,398 | 27th |
Pay ratio
| Daniel R. Hart's Pay | $788,389 |
|---|---|
| Median Employee's Pay | $96,570 |
| Pay Ratio | 8to 1 |
In 2019, the annual total compensation of Daniel R. Hart was $788,389.
The annual total compensation of the median employee at Peregrine Pharmaceuticals was $96,570.
The ratio of Daniel R. Hart's pay to the pay of median employee was therefore 8 to one.
Hart's colleagues
We found four more compensation records of executives who worked with Daniel R. Hart at Peregrine Pharmaceuticals in 2019.
2019
Roger Lias
Peregrine Pharmaceuticals
Chief Executive Officer
2019
Mark Ziebell
Peregrine Pharmaceuticals
General Counsel
2019
Stephen Hedberg
Peregrine Pharmaceuticals
Principal Financial Officer and Principal Accounting Officer
2019
Paul Lytle
Peregrine Pharmaceuticals
Chief Financial Officer
News
August 28, 2023
August 29, 2022
August 27, 2021
August 27, 2020
August 21, 2019